Literature DB >> 10650934

Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells.

S Monno1, M V Newman, M Cook, W L Lowe.   

Abstract

Insulin-like growth factor I (IGF-I) is an important mediator of breast cancer cell growth, although the signaling pathways important for IGF-I-mediated effects in breast cancer cells are still being elucidated. We had demonstrated previously that increased intracellular cAMP in MCF-7 breast cancer cells inhibited cell growth and IGF-I-induced gene expression, as determined using a reporter gene assay. This effect of cAMP on IGF-I signaling was independent of IGF-I-induced activation of the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1 and -2). To determine whether this effect of cAMP may be mediated via another mitogen-activated protein kinase, the ability of IGF-I to activate the c-Jun N-terminal kinases (JNKs) was investigated. Treatment of MCF-7 cells with 100 ng/ml IGF-I increased the level of phosphorylated JNK, as determined by Western blot analysis. JNK phosphorylation was not evident until 15 min after treatment with IGF-I, and peak levels of phosphorylation were present at 30-60 min. This was in contrast to ERK phosphorylation, which was present within 7.5 min of IGF-I treatment. Determination of JNK activity using an immune complex assay demonstrated a 3.3- and 3.5-fold increase in JNK1 and -2 activity, respectively, 30 min after treatment with 100 ng/ml IGF-I. The use of PD98059, which inhibits activation of ERK1 and -2, and LY 294002, an inhibitor of phosphatidylinositol 3-kinase, demonstrated that IGF-I-induced activation of JNK1 is independent of ERK and phosphatidylinositol 3-kinase activation. In contrast, increasing intracellular cAMP with forskolin resulted in abrogation of IGF-I-induced JNK activity. In summary, these data demonstrate that IGF-I activates the JNKs in MCF-7 breast cancer cells and, taken together with the results of our previous study, suggest that JNK may contribute to IGF-I-mediated gene expression and, possibly, cell growth in MCF-7 breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10650934     DOI: 10.1210/endo.141.2.7307

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Immunochemical analysis of protein expression in breast epithelial cells transformed by estrogens and high linear energy transfer (LET) radiation.

Authors:  Gloria M Calaf; Debasish Roy; Tom K Hei
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

2.  Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells.

Authors:  G Liu; D M Bibus; A M Bode; W Y Ma; R T Holman; Z Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

3.  IGF and insulin receptor signaling in breast cancer.

Authors:  Antonino Belfiore; Francesco Frasca
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-19       Impact factor: 2.673

4.  Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells.

Authors:  B Wen; E Deutsch; E Marangoni; V Frascona; L Maggiorella; B Abdulkarim; N Chavaudra; J Bourhis
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

Review 5.  Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.

Authors:  Jacqueline Whyte; Orla Bergin; Alessandro Bianchi; Sara McNally; Finian Martin
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.